Art

J-GLOBAL ID：202002243084018709   Reference number：20A2807635

Current Status and Future Perspectives of Companion Diagnostics

コンパニオン診断薬の現状と今後の展望

Author (3)： TSUKUMO YOSHINORI (国立医薬品食品衛研) ,  SUZUKI TAKAYOSHI (国立医薬品食品衛研) ,  INOUE TAKAO (国立医薬品食品衛研)
Material： 医薬品医療機器レギュラトリーサイエンス  (Pharmaceutical and Medical Device Regulatory Science)
Volume： 51  Issue： 12  Page： 638-648  Publication year： Dec. 10, 2020 
JST Material Number： F0456B  ISSN： 1884-6076  CODEN： IIKRA9  Document type： Article
Article type： 文献レビュー  Country of issue： Japan (JPN)  Language： JAPANESE (JA)

Thesaurus term： human(primates) ,...
Semi thesaurus term： *companion diagnostics ,...

Register(free) or Log In to access     To see more with JDream III (charged).   {{ this.onShowAbsJLink("http://jdream3.com/lp/jglobal/index.html?docNo=20A2807635&from=J-GLOBAL&jstjournalNo=F0456B") }}

JST classification (3)： Clinical application of antitumor(=antineoplastic)drugs  (GW16020L) ,  Clinical application of diagnostic drugs  (GW20020A) ,  Gene manipulation  (EC02050B)

Reference (32)：

• Gleevec approval letter, http://www.accessdata.fda.gov/drugsatfda_docs/nda/2001/21-335_Gleevec_Approv.pdf.
• Druker, BJ.; Talpaz, M.; Resta, DJ.; Peng, B.; Buchdunger, E.; Ford, JM.; Lydon, NB.; Kantarjian, H.; Capdeville, R; Ohno-Jones, S.; Sawyers, CL. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med. 2001, 344(14), p.1031-1037.
• Druker, BJ.; Sawyers, CL.; Kantarjian, H.; Resta, DJ.; Reese, SF.; Ford, JM.; Capdeville, R.; Talpaz, M. Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome. N Engl J Med 2001, 344 (14), p.1038-1042.
• Paez, JG.; Jänne, PA.; Lee, JC.; Tracy, S.; Greulich, H.; Gabriel, S.; Herman, P.; Kaye, FJ.; Lindeman, N.; Boggon, TJ.; Naoki, K.; Sasaki, H.; Fujii, Y.; Eck, MJ.; Sellers, WR.; Johnson, BE.; Meyerson, M. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science. 2004, 304 (5676), p.1497-1500.
• Mitsudomi, T.; Kosaka, T.; Endoh, H.; Horio, Y.; Hida, T.; Mori, S.; Hatooka, S.; Shinoda, M.; Takahashi, T.; Yatabe, Y. Mutations of the epidermal growth factor receptor gene predict prolonged survival after gefitinib treatment in patients with non-small-cell lung cancer with postoperative recurrence. J Clin Oncol. 2005, 23 (11), p.2513-2520.

Terms in the title (3)： コンパニオン診断薬 ,  現状 ,  展望